高危激素受体阳性人表皮生长因子受体2阴性乳腺癌中的循环肿瘤DNA与晚期复发
该前瞻性研究纳入103例诊断超过5年、无临床复发证据的高危II-III期激素受体阳性乳腺癌患者,通过肿瘤知情个体化ctDNA检测微小残留病。8例(10%)MRD阳性,6例(7.2%)发生远处转移且均MRD阳性,中位ctDNA领先时间12.4个月。
要点
- 高危HR+乳腺癌诊断5年后,10%(8/103)患者ctDNA-MRD阳性。
- 7.2%(6/103)发生远处转移,均先于临床复发检出MRD,中位领先12.4个月。
- 1例局部复发患者未检出MRD。
核心结论
- 在高危HR+乳腺癌晚期辅助治疗背景下,ctDNA中位提前约1年可检出所有远处转移病例。
- 未来研究将确定ctDNA指导的干预能否改变HR+乳腺癌患者的临床结局。
研究设计与样本
- 前瞻性研究,纳入103例诊断超过5年、无临床复发证据的高危II-III期HR+乳腺癌患者。
- 对原发肿瘤组织行全外显子测序,设计个体化肿瘤知情ctDNA检测以检出微小残留病(MRD)。
- 在知情同意时及每6-12个月常规随访时采集血浆,随访临床复发。
主要发现
- 103例中85例有足够肿瘤组织,85例中83例(97.6%)全外显子测序成功。
- 个体化ctDNA检测针对中位36个变异设计,共检测219份血浆样本。
- 从诊断至首次采样的中位时间为8.4年,自诊断中位随访10.4年,自首次采样中位随访2.0年,每例中位血浆样本数为2份。
- 8例(10%)在任何时间点MRD检测阳性;6例(7.2%)发生远处转移,均MRD阳性先于临床复发,中位ctDNA领先时间12.4个月。
- 1例(1.2%)局部复发患者未检出MRD;8例MRD阳性患者中2例末次随访时未临床复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor-positive breast cancer (HR+ BC) more than 5 years from diagnosis. METHODS: We enrolled 103 patients with high-risk stage II-III HR+ BC diagnosed more than 5 years prior without clinical evidence of recurrence. We performed whole-exome sequencing (WES) on primary tumor tissue to identify somatic mutations tracked via a personalized, tumor-informed ctDNA test to detect minimal residual disease (MRD). We collected plasma at the time of consent and at routine visits every 6-12 months. Patients were followed for clinical recurrence. RESULTS: In total, 85 of 103 patients had sufficient tumor tissue; of them, 83 of 85 (97.6%) patients had successful whole-exome sequencing. Personalized ctDNA assays were designed targeting a median of 36 variants to test 219 plasma samples. The median time from diagnosis to first sample was 8.4 years. The median follow-up was 10.4 years from diagnosis and 2.0 years from first sample. The median number of plasma samples per patient was two. Eight patients (10%) had positive MRD testing at any time point. Six patients (7.2%) developed distant metastatic recurrence, all of whom were MRD-positive before overt clinical recurrence, with median ctDNA lead time of 12.4 months. MRD was not identified in one patient (1.2%) with local recurrence. Two of eight MRD-positive patients had not had clinical recurrence at last follow-up. CONCLUSION: In this prospective study, in patients with high-risk HR+ BC in the late adjuvant setting, ctDNA was identified a median of 1 year before all cases of distant metastasis. Future studies will determine if ctDNA-guided intervention in patients with HR+ BC can alter clinical outcomes.
引用
- Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022. PMID: 35658506. doi:10.1200/JCO.22.00908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。